Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Adipic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | NSD2 | O96028 | 1/20 | 0.38 |
| ▸ | ABL1 | P00519 | 1/20 | 0.38 |
| ▸ | IDE | P14735 | 1/20 | 0.38 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 4/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.35 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.35 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | PPARG | P37231 | 5/20 | 0.34 |
| ▸ | PPARD | Q03181 | 5/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hexanoate SCHEMBL21404079 | 0.94 | AKR1B1 (0.47) | TDP1LMNATSHRAKR1B1MEN1 | |
| Creatinine SCHEMBL21404062 | 0.93 | CRBN (0.45) | CRBNTDP1GAALMNATSHR | |
| Stearic Acid SCHEMBL21404066 | 0.93 | GPR84 (0.49) | TDP1LMNATSHRAKR1B1MEN1 | |
| Azelaic Acid SCHEMBL16540658 | 0.89 | CRBN (0.34) | CRBNTDP1GAANSD2ABL1 | |
| Creatinine SCHEMBL21404094 | 0.86 | CRBN (0.45) | CRBNTDP1GAAMEN1KMT2A | |
| Creatinine SCHEMBL27811809 | 0.86 | CRBN (0.52) | CRBNTDP1GAAMEN1KMT2A | |
| Creatinine SCHEMBL2248139 | 0.86 | CRBN (0.56) | CRBNTDP1GAAPTGS1LMNA | |
| Oleic Acid SCHEMBL21404069 | 0.85 | PPARG (0.56) | TDP1PTGS1LMNATSHRKMT2A | |
| Glutamic Acid SCHEMBL18335507 | 0.82 | GRM5 (0.50) | CRBNLMNAPMP22KMT2AALOX15 | |
| Creatinine SCHEMBL28491793 | 0.82 | CRBN (0.56) | CRBNTDP1GAAPTGS1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230201115-A1 | CREATINE AND/OR CREATININE COMPOSITIONS AND RELATED METHODS | THERMOLIFE INTERNATIONAL, LLC | 2023-06-29 | — | — | US | disclosed |
| US-20230062170-A1 | CREATINE AND/OR CREATININE COMPOSITIONS AND RELATED METHODS | THERMOLIFE INTERNATIONAL, LLC | 2023-03-02 | — | — | US | disclosed |
| US-11154499-B2 | Creatine and/or creatinine compositions and related methods | THERMOLIFE INTERNATIONAL, LLC (US) | 2021-10-26 | — | — | US | disclosed |
| US-20210251895-A1 | CREATINE AND/OR CREATININE COMPOSITIONS AND RELATED METHODS | THERMOLIFE INTERNATIONAL, LLC | 2021-08-19 | — | — | US | disclosed |
| US-20200246262-A1 | CREATINE AND/OR CREATININE COMPOSITIONS AND RELATED METHODS | THERMOLIFE INTERNATIONAL, LLC (US) | 2020-08-06 | — | — | US | disclosed |
| WO-2019191338-A1 | CREATINE AND/OR CREATININE COMPOSITIONS AND RELATED METHODS | THERMOLIFE INTERNATIONAL, LLC (US) | 2019-10-03 | — | — | WO | disclosed |
| US-20190298667-A1 | CREATINE AND/OR CREATININE COMPOSITIONS AND RELATED METHODS | THERMOLIFE INTERNATIONAL, LLC | 2019-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200246262-A1 | CREATINE AND/OR CREATININE COMPOSITIONS AND RELATED METHODS | MB, CKMT1A; CKMT1B, REN | CRBN 225/4885TDP1 2771/4885GAA 806/4885 |
| US-11154499-B2 | Creatine and/or creatinine compositions and related methods | MB, CKMT1A; CKMT1B, REN | CRBN 225/4885TDP1 2771/4885GAA 806/4885 |
| US-20190298667-A1 | CREATINE AND/OR CREATININE COMPOSITIONS AND RELATED METHODS | CKMT1A; CKMT1B, REN, ALB | CRBN 591/4885TDP1 1789/4885GAA 958/4885 |
| US-20230201115-A1 | CREATINE AND/OR CREATININE COMPOSITIONS AND RELATED METHODS | CKMT1A; CKMT1B, REN, ALB | CRBN 842/4885TDP1 1705/4885GAA 514/4885 |
| US-20230062170-A1 | CREATINE AND/OR CREATININE COMPOSITIONS AND RELATED METHODS | CKMT1A; CKMT1B, REN, ALB | CRBN 591/4885TDP1 1789/4885GAA 958/4885 |
| US-20210251895-A1 | CREATINE AND/OR CREATININE COMPOSITIONS AND RELATED METHODS | MB, CKMT1A; CKMT1B, REN | CRBN 225/4885TDP1 2771/4885GAA 806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.